Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases

Abstract

The objective of the study was to compare the clinical value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 242 (CA242) in diagnosis and prognosis for 5-year recurrence-free survival (RFS) in patients with colorectal cancer (CRC). Preoperative serum CA19-9 and CA242 concentrations were detected by C12 protein chip diagnostic system in 185 patients with CRC, and informative data were collected during 5-year follow-up periods. The value of CA19-9 and CA242 in diagnosis and prognosis for 5-year RFS as well as their consistencies and correlations were comparatively analyzed. The sensitivities of CA19-9 and CA242 were only 19.5 and 20%, respectively; the efficiencies of two TMs were 53.9 and 54.2%, respectively; and two TMs increased significantly with advancing clinical stages (P < 0.0001). Preoperative CA19-9 and CA242 levels correlated with stage (r, 0.411 and 0.408) and CEA concentration (r, 0.553 and 0.630). The concentrations of two TMs closely correlated with each other (r = 0.829), and two TMs had a very strong consistency in diagnosis (κ = 0.931). Among 88 of 185 cases with complete follow-up information on RFS, patients with positive preoperative serum CA19-9 or CA242 had higher 5-year recurrent rates (72.2% vs. 44.3%, P = 0.034; 76.5% vs. 43.7%, P = 0.015) and reduced median RFS (14 vs. 36 months, 12 vs. 36 months) compared with those with negative TMs. The consistency of predicting prognosis for RFS of two TMs was extremely strong (κ = 0.964). ROC curves analysis showed that CA242 test performed better than CA19-9 test (AUC, 0.648 vs. 0.605). Univariate analysis showed that preoperative serum status of both TMs was correlated with 5-year RFS (P < 0.05), whereas multivariate Cox regression model analysis revealed that none of them were independent prognostic factors for RFS. Both CA19-9 and CA242 had strong consistencies in diagnosis and prognosis for predicting 5-year RFS. CA242 demonstrated superior value to CA19-9 in CRC.

Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer

“…Some studies have reported that CA 242 has superior value in pancreatic carcinoma and colorectal carcinoma (Carpelan-Holmstrom et al, 1996;Ni et al, 2005;Yang et al, 2012), but few have examined the relationship between these two tumor markers and gastric cancer. Our study analyzed the levels of expression of CA 242 and CA 50 in gastric cancer patients, finding that serum CA 242 and CA 50 levels had a significant positive correlation with the lymph node status and tumor stage.…”

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

“…Pancreatic cancer has been the leading clinical application for CA242 because of its excellent performance in this cancer. Some small-scale studies have investigated CA242 in gallbladder carcinoma and cholangiocarcinoma [7,14,25,28], but due to the sample size or quality of these studies, the credible AUC values for these two carcinomas are still unknown. Therefore, our ndings indicate that CA242 is also suitable for use as a biomarker for cholangiocarcinoma and gallbladder cancer, whose AUCs were 0.8145 (0.7737, 0.8553) and 0.8349 (0.8157, 0.8542), respectively ( Table 1).…”

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

“…We found that CA242 levels were elevated in a variety of digestive system cancers, including pancreatic cancer, gallbladder cancer, cholangiocarcinoma, colorectal cancer, and gastric cancer, which was consistent with previous reports. The AUC values of the ROC curves for pancreatic cancer, gallbladder carcinoma, and cholangiocarcinoma were all greater than 0.8, but only pancreatic cancer has been studied in detail [4,10,13,17,22,[25][26][27]. Previous studies have shown that CA242 alone or in combination with other biomarkers can predict the diagnosis, progression, and prognosis of pancreatic cancer [4, 7, 10, 12-16, 23, 24].…”